Holdings of Opaleye Management Inc.
48 declared positions · as of Mar 31, 2026
Original filing · Ten largest lines: 68.1 % of the equity sleeve
Sector breakdown
Titelia classification, company by company. The unattributed share stays visible.
Currency breakdown
The quoted currency of each line, as declared.
Country breakdown
Shares computed on the equity sleeve.
| Country | Lines | Value | Share |
|---|
| US | 48 | 636.5M $ | 100.00 % |
Positions
| Company | Shares | Value | Weight |
|---|
| Harrow Inc | 2,832,230 | 99.9M $ | |
| Liquidia Corp | 2,545,000 | 88.8M $ | |
| Eton Pharmaceuticals Inc | 2,860,000 | 70.6M $ | |
| Rhythm Pharmaceuticals Inc | 123,000 | 35.3M $ | |
| Apogee Therapeutics Inc | 390,000 | 32.8M $ | |
| Disc Medicine Inc | 421,000 | 26.9M $ | |
| Stoke Therapeutics Inc | 700,000 | 22.8M $ | |
| Perspective Therapeutics Inc | 4,675,000 | 19.5M $ | |
| Rezolute Inc | 6,300,000 | 19.2M $ | |
| TG Therapeutics Inc | 535,000 | 17.8M $ | |
| SANUWAVE Health Inc | 981,267 | 17M $ | |
| Edgewise Therapeutics Inc | 500,000 | 15.8M $ | |
| Annexon Inc | 2,331,761 | 12.9M $ | |
| Alumis Inc | 550,000 | 12.1M $ | |
| Codexis Inc | 6,785,000 | 11.1M $ | |
| Protagonist Therapeutics Inc | 100,000 | 10.5M $ | |
| Revolution Medicines Inc | 100,000 | 9.7M $ | |
| XOMA Royalty Corp | 300,000 | 9.4M $ | |
| Q32 Bio Inc | 1,256,228 | 8.1M $ | |
| MBX Biosciences Inc | 260,000 | 7.8M $ | |
| Relmada Therapeutics Inc | 935,000 | 6.5M $ | |
| CG oncology Inc | 94,800 | 6.4M $ | |
| JADE BIOSCIENCES INC | 427,608 | 6M $ | |
| Ocular Therapeutix Inc | 600,000 | 5.1M $ | |
| Assertio Holdings Inc | 265,707 | 5.1M $ | |
| Editas Medicine Inc | 1,926,997 | 4.8M $ | |
| Sutro Biopharma Inc | 190,671 | 4.7M $ | |
| Journey Medical Corp | 960,000 | 4.5M $ | |
| Voyager Therapeutics Inc | 1,150,000 | 4.4M $ | |
| Trevi Therapeutics Inc | 345,100 | 4.1M $ | |
| Tectonic Therapeutic Inc | 123,000 | 3.8M $ | |
| Cabaletta Bio Inc | 1,380,000 | 3.7M $ | |
| BIODESIX INC | 238,047 | 3.5M $ | |
| Rocket Pharmaceuticals Inc | 955,000 | 3.4M $ | |
| Zentalis Pharmaceuticals Inc | 1,412,656 | 3.3M $ | |
| Intellia Therapeutics Inc | 245,000 | 3.1M $ | |
| Fortress Biotech Inc | 1,042,000 | 2.9M $ | |
| Opus Genetics Inc | 1,120,000 | 2.3M $ | |
| Rigel Pharmaceuticals Inc | 70,000 | 1.9M $ | |
| Atea Pharmaceuticals Inc | 322,600 | 1.7M $ | |
| Lyell Immunopharma Inc | 79,097 | 1.6M $ | |
| Enanta Pharmaceuticals Inc | 125,000 | 1.6M $ | |
| NextCure Inc | 141,181 | 1.5M $ | |
| 4D Molecular Therapeutics Inc | 112,291 | 1M $ | |
| Protalix BioTherapeutics Inc | 340,000 | 737.8K $ | |
| BridgeBio Oncology Therapeutics Inc | 53,282 | 476.9K $ | |
| LB Pharmaceuticals Inc | 14,506 | 357.7K $ | |
| ADAGIO MEDICAL HOLDINGS INC | 18,444 | 21.2K $ | |